Day: August 11, 2021

Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Written by Customer Service on August 11, 2021. Posted in Public Companies.

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding public warrants Received Fast Track designation and initiated screening in Phase 2a trial of CVL-871 in dementia-related apathy Virtual R&D Update Event scheduled for October 7, 2021 Conference call and webcast scheduled today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended June 30, 2021 and provided key pipeline and business updates. “This quarter we began to deliver on Cerevel’s aspiration to become the premier neuroscience...

FTC Solar Announces Second Quarter 2021 Financial Results

Written by Customer Service on August 11, 2021. Posted in Public Companies.

Second Quarter Highlights and Recent DevelopmentsSecond quarter revenue of $50.1 million; total 1H’21 revenue up 39% y/y; Added to executed contracts and awarded orders, now totaling $419 million YTD through Aug. 1*; Continuing to win new customers, including another top 5 construction firm/EPC; Recognized first revenue for our SunPath software solution; Sold stake in minority investment (Dimension Energy) for $22 million; and Targeting significant 2H’21 revenue growth, with increased logistics cost impact in Q3 followed by significant progress toward profitability in Q4 AUSTIN, Texas , Aug. 11, 2021 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a fast-growing global provider of solar tracker systems, software and engineering services, today announced financial results for the second quarter ended June 30, 2021. “Revenue...

WIRELESS TELECOM GROUP ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS

Written by Customer Service on August 11, 2021. Posted in Public Companies.

Highlights for the quarter ended June 30, 2021:● Net revenues of $12.0 million, an increase of 8.2% from the same period last year, and up 6.2% from the 2021 first quarter● Gross profit of $6.1 million, gross profit margin of 51.0%, representing the fifth straight quarter of consolidated gross profit margin greater than 50%● Operating income of $165,000, compared to an operating loss of $59,000 in the same period last year● Net income of $1.5 million which includes gain on extinguishment of PPP loan of $2.0 million, compared to a net loss of $668,000 in the same period last year● Non-GAAP adjusted EBITDA of $864,000, compared to a non-GAAP adjusted EBITDA of $794,000 in the same period last year● New customer orders of $14.5 million, a book-to-bill ratio of 1.21● Backlog of $12.5 million, an increase of $6.3 million...

DFDS: MONTHLY VOLUME REPORT: FREIGHT VOLUMES CONTINUED GROWING IN JULY

Written by Customer Service on August 11, 2021. Posted in Public Companies.

INVESTOR NEWS NO. 25/2021 Ferry – freight: Total volumes in July 2021 were 3.3% above 2020. Net adjustments for structural route changes reduced growth 1.8 ppt to 1.5%. The volumes transported in July 2021 by the North Sea, Baltic Sea and Mediterranean business units were well above July 2020 supported by investments in new and more efficient capacity. Freight capacity in this part of the route network was to a large extent re-established in July 2020 following the lockdowns in Q2 2020. Volumes for these business units were also above 2019. Channel volumes were below 2020, adjusted for the Dunkirk-Rosslare route opened at the beginning of 2021. This follows an overall market decrease and reintroduction of capacity that was taken out of the market by a ferry operator in 2020. Ferry – passenger: The total number of passengers in...

Berkeley Lights Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 11, 2021. Posted in Earnings Releases And Operating Results.

Second quarter revenue grew 82% year over year EMERYVILLE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended June 30, 2021. Recent HighlightsGrew total revenue to $19.3 million for the second quarter of 2021, representing an 82% year over year growth and bringing first half revenue to $37.9 million, a 56% increase over the first half of 2020Expanded the installed base to 92 platforms, with seven new direct placements shipped in the quarterLaunched TechAccess subscription model expanding customer access to the Berkeley Lights platformReleased Opto Plasma B Discovery 4.0, an industry-leading functional antibody discovery workflow, which significantly increases recovered sequence diversity and reduces the...

Berkeley Lights and Bayer announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits

Written by Customer Service on August 11, 2021. Posted in Public Companies.

Agreement debuts Berkeley Lights’ rapid high-throughput functional screening capability to accelerate and expand the discovery and development of Bayer Crop Science’s seeds and traits product pipeline EMERYVILLE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI) a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed. Berkeley Lights will leverage its platform to screen individual variants of bioactives for Bayer in a massively high-throughput manner. The outcome will be a significant acceleration of the agricultural leader’s pipeline for discovery and development of novel traits....

Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights

Written by Customer Service on August 11, 2021. Posted in Public Companies.

– Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – – Clinical Trial Application in Europe accepted for Phase 1/2 trial of INZ-701 in ABCC6 Deficiency – – Investigational New Drug application in U.S. accepted for Phase 1/2 trial of INZ-701 in ABCC6 Deficiency – – Expect to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash, cash equivalents, and investments expected to support continued operations into the fourth quarter of 2022 – BOSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...

Barnwell Fiscal Q3 Revenue Increases 28% in the quarterly period to $5.1 Million, Reports Net Earnings of $5.0 Million and $0.59 Net EPS; Regains Compliance with NYSE

Written by Customer Service on August 11, 2021. Posted in Public Companies.

Strong financial results demonstrate significant improvements and turnaround of the company HONOLULU, Aug. 11, 2021 (GLOBE NEWSWIRE) — Barnwell Industries, Inc. (NYSE American: BRN) today reported results for the three and nine-months ended June 30, 2021. HighlightsQ3 Revenue increased 28% in the quarterly period to $5.1 million Q3 Net earnings were $5.0 million, compared to a net loss of $3.5 million Q3 Net earnings per share was $0.59, compared to a $0.42 net loss per share Nine-month net earnings was $4.7 million, compared to a loss of $5.4 million Nine-month net earnings per share was $0.57, compared to a $0.65 net loss per shareMr. Alexander Kinzler, Chief Executive Officer of Barnwell, commented, “Our significantly improved results for this quarter as compared to the prior year quarter were due primarily to a $4,227,000...

Atotech Reports Second Quarter 2021 Results and Raises 2021 Full Year Guidance

Written by Customer Service on August 11, 2021. Posted in Mergers And Acquisitions.

Generates second quarter revenue of $377 million, an increase of 44% over the prior year period, including chemistry organic revenue growth of 24% Reports net income of $30 million, compared to a net loss of $283 million in Q2 2020, the latter caused by Covid-19 pandemic-related impairment charges Delivers a record Adjusted EBITDA of $118 million, a 63% increase over the prior year period Reduces net leverage to 3.2x Raises guidance for full year 2021 organic revenue growth, which is now expected to be in the range of 13% to 14%, including full year chemistry organic revenue growth of approximately 10% Increases guidance for full year 2021 Adjusted EBITDA1, which is now anticipated to be in the range of $435 million to $450 million, an increase of $18 million over the prior guidance at the mid-pointBERLIN, Aug. 11, 2021 (GLOBE NEWSWIRE)...

Research 2021, Adhesive Bandages Market Size, Share, Growth, Trends, Revenue, Competitive Analysis, Forecast

Written by Customer Service on August 11, 2021. Posted in Mergers And Acquisitions.

Key Companies Covered in the Adhesive Bandages Market Research Report are Johnson & Johnson Services, Inc., Beiersdorf AG, 3M, Goldwin Medicare, Aso LLC, Precision Coatings Pvt Ltd, L&R USA INC., ConvaTec Inc., Medline Industries, Inc., Elkem ASA and Others. Pune, India, Aug. 11, 2021 (GLOBE NEWSWIRE) — Increasing prevalence of chronic wounds, accidents and burns is a key factor driving the global adhesive bandages market, says Fortune Business Insights in a report, titled “Adhesive Bandages Market Size, Share and Global Trend by Product (Medicated Bandages, Non- Medicated Bandages), By Material (Fabric, Plastic, Latex), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026.” Adhesive bandages are likely to witness huge demand due to its composition as...

Day: August 11, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice